- Home
- Companies
- Meissa Vaccines, Inc.
- Products
- Meissa - RSV Live Attenuated Vaccine ...
Meissa - RSV Live Attenuated Vaccine Candidate
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response in participants (adults and young children), who had previously been infected and already had circulating antibodies to RSV in their blood (ClinicalTrials.gov identifiers NCT04444284 and NCT04227210).
These results differentiate Meissa’s RSV vaccine from other live attenuated RSV vaccine candidates and are consistent with previous animal studies, in which Meissa’s RSV vaccine candidate was highly attenuated yet led to robust immune responses and protected both the upper and lower respiratory tracts from RSV challenge. MV-012-968 is currently being tested in a Phase 2a, randomized, double-blind, placebo-controlled challenge study, designed to evaluate the safety and prophylactic efficacy of the Meissa vaccine against symptomatic RSV infection (ClinicalTrials.gov identifier: NCT04690335).
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States and is considered a “missing” mandatory pediatric vaccine. RSV is also a significant cause of morbidity and mortality in older adults. In the United States, approximately 1% of infants are hospitalized by RSV each year. Globally, RSV causes more than 118,000 deaths per year and over 3 million hospitalizations in children less than five years of age (Anderson 2013).